CopyPastehas never been so tasty!

The Pharmaceutical Market : Finland

by anonymous

  • 0
  • 0
  • 0
62 views

The macroenvironment for the Finnish pharmaceutical industry is improving. Politically, the new six-party coalition is larger and represents a broader spectrum of opinion than is usual, which could make it unstable. However, the Economist Intelligence Unit (EIU) believes that it will last out its four-year term. Economically, recovery from the downturn is stalling due to the euro area debt crisis. Legally, Finland remains on the USTR’s Watch List in 2011 due to concerns over patent protection. Demographically, Finland has one of the largest proportions of population over the age of 65 in Western Europe. Latest projections expect that the population aged 65 and over will constitute more than one-fifth of the total population by 2017. The ageing population means that healthcare is increasingly focused on preventative care. http://www.bharatbook.com/market-research-reports/healthcare-market-research-report/the-pharmaceutical-market-finland.html

The Finnish government has introduced several cost-containment measures in recent years in an effort to curb rising healthcare costs. One of the latest affecting the pharmaceutical market in Finland is a reference pricing system. It is hoped that the new system will reduce the use of expensive pharmaceutical products, thus lowering the costs for patients and reducing the pressure to raise health insurance payments. Generic substitution in Finland has been extended to include products with an analogy process patent. As a result, generic substitution will be more effective in terms of saving money, but Finnish manufacturers of patented original products now enter generic price competition several years before product patents expire in other European countries.

There are three leading domestic producers in Finland; Orion, Verman and Vitabalans. Multinational companies Bayer and Santen also have production facilities in Finland. The top ten pharmaceutical companies in Finland had combined sales of over 1.0 billion euros at wholesale prices in 2010, equal to a share of over half of the market. The leading company was Orion, with a market share of nearly 10.0%. This was followed by Pfizer, Novartis, AstraZeneca and GlaxoSmithKline. In the biologic sector, Biotie Therapies completed its acquisition of Synosia Therapeutics in February 2011, while Ark Therapeutics entered into a formal agreement to divest the majority of its woundcare business in the same month.

PROVIDING STRATEGIC MARKET ANALYSIS EVERY MONTH

Espicom's highly-regarded world pharmaceutical market research reports provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:

Market size and trends impacting the development of the market.
Five-year projections for market indicators such as health spending.
Regulations on drug applications & approvals, pricing & reimbursement as well as wholesaling and retail.
Specialised intelligence on generics and biological medicines.
Foreign and local company profiles

EXECUTIVE SUMMARY.. 1
Snapshot: Strategic Espicom Analysis..2
Snapshot: Key Data Projections3
MACROENVIRONMENT 4
POLITICAL..4
ECONOMIC 5
Projections .5
LEGAL...6
EU Patent Protection & Intellectual Property Rights.....6
Proposal for Unitary Patent 6
Finland Remains on the USTR’s Watch List in 2011 .. 6
EU Supplementary Protection Certificates...6
EU Data Exclusivity6
DEMOGRAPHIC ....7
Projections .7
Demographic Indicators...8
Birth Rate . 8
Death Rate..... 8
Infant Mortality .. 8
Life Expectancy at Birth 8
EPIDEMIOLOGY. 9
DISEASE BURDEN.9
DISEASE PREVALENCE...10
Communicable Diseases.10
HIV/AIDS. 10
Non-Communicable Diseases ....11
Cancer..... 11
Diabetes. 11
HEALTHCARE - ACCOMPANYING HEALTH STATISTICS .. 12
EU DIRECTIVE12
Cross-Border Healthcare Directive ..12
NATIONAL AUTHORITY.12
Ministry of Social Affairs and Health .....12
ORGANISATION..13
EXPENDITURE.....14
Projections .....14
Latest Figures.15
INFRASTRUCTURE....17
Hospital Infrastructure ...17
Outpatient Infrastructure.....17
SERVICES..18
Hospital Inpatient Services ..18
Outpatient Services...18
WORKFORCE.19
Projections .....19
Physicians.19
Nurses.21
Dentists ....21
Pharmacists....21
REGULATORY AFFAIRS ..... 22
EU REGULATORY AUTHORITY. 22
NATIONAL AUTHORITY 22
Fimea ..22
MARKETING REGISTRATION.... 22
EU Marketing Registration...22
Centralised Procedure.22
National Procedures..23
Marketing Authorisations.23
Clinical Trials23
Authorised Pharmaceuticals..23
PROMOTION 23
Advertising ....23
PRICING & REIMBURSEMENT. 24
EU NETWORKING MEETING24
NM CAPR...24
PRICING ...24
REIMBURSEMENT ... 25
Basic Reimbursement..25
Special Reimbursement....25
Reimbursement Categories & Reimbursement Rates26
DISTRIBUTION CHANNELS..... 27
EU DIRECTIVE27
Falsified Medicines Directive27
DRUG WHOLESALING....27
Association of Wholesalers...27
Association of Pharmaceutical Distributors27
Leading Wholesalers.27
Magnum Medical ...27
Oriola27
Tamro27
DRUG RETAILING..... 28
Association of Community Pharmacies.28
Association of Finnish Pharmacies....28
MARKET ANALYSIS 29
SIZE.... 29
Projections .....29
Historical Figures.30
Current Structure.31
Hospital Sector..32
PRODUCT DEVELOPMENT..33
EU Programmes...33
Horizon 2020.....33
IMI33
National Research & Development..33
MANUFACTURING....35
TRADE ..... 36
Exports .....36
Imports.....39
Balance of Trade ..43
COMPETITION..44
TRADE ASSOCIATION.... 44
Pharma Industry Finland..44
COMPANY INTELLIGENCE.. 45
Domestic Producers ..45
Orion.45
Verman...45
Vitabalans....45
Multinational Manufacturers.....45
Bayer.45
Santen ....45
OTC PHARMACEUTICALS..46
MARKET SIZE 46
GENERIC PHARMACEUTICALS ..... 47
REGULATION.47
EU Marketing Registration...47
PRICING & REIMBURSEMENT...47
BIOLOGICS & BIOSIMILARS ... 49
REGULATION 49
EU Approval Process..49
EU Regulation of Biosimilars .....49
EMA Guideline Documents...50
Draft Biosimilar Concept Paper...50
Biosimilar mAb Guideline.50
Biosimilars Approved in the EU..50
COMPETITION.....51
Trade Association 51
Finnish Bioindustries .. 51
Company Intelligence.....51
Ark Therapeutics.... 51
Biotie Therapies 51
FIT Biotech... 51
Oncos Therapeutics.....52
Competitive Strategies ...52
CONCLUSIONS: OPPORTUNITIES & CHALLENGES ... 53
Strategic Espicom Analysis.53
MACROENVIRONMENT....53
EPIDEMIOLOGY....53
HEALTHCARE..53
REGULATORY AFFAIRS.....54
PRICING & REIMBURSEMENT54
DISTRIBUTION CHANNELS ....55
MARKET....55
COMPETITION 55
OTC PHARMACEUTICALS.56
GENERIC PHARMACEUTICALS.....56
BIOLOGICS & BIOSIMILARS...56
Radar Analysis... 58
SWOT Analysis... 58
DIRECTORY 59
GOVERNMENT ORGANISATIONS...59
PHARMACEUTICAL DISTRIBUTORS.....59
PHARMACEUTICAL PRODUCERS ...59
Domestic Producers ..59
Multinational Manufacturers.....59
Biologic Companies...59
TRADE ORGANISATIONS.....59

For more information kindly visit :
The Pharmaceutical Market : Finland

Or

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: https://twitter.com/BharatBook
Our Blogs: http://in.linkedin.com/pub/bharat-book/3a/98/512
http://financemarketreports.blogspot.com/

Add A Comment: